Can I read Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I) on EtoBox?

Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I) by Felix C Popp; Barbara Fillenberg; Elke Eggenhofer; Philipp Renner; Johannes Dillmann; Volker Benseler; Andreas A Schnitzbauer; James Hutchinson; Robert Deans; Deborah Ladenheim; Cheryl A Graveen; Florian Zeman; Michael Koller; Martin J Hoogduijn; Edward K Geissler; Hans J Schlitt; Marc H Dahlke is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I) about?

## Background Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to be reduced. In the current protocol, we propose to complement immunosuppressive pharmacotherapy with third-party multipotent adult progenitor cells (MAPCs), a culture-selected population of adult adherent stem cells derived from bone marrow that has been shown to display potent immunomodulatory and regenerative properties. In animal models, MAPCs reduce the need for pharmacological immunosuppression after experimental solid organ transplantation and regenerate damaged organs. ## Methods Patients enrolled in this phase I, single-arm, single-center safety and feasibility study (n = 3-24) will receive 2 doses of third-party MAPCs after liver transplantation, on days 1 and 3, in addition to a calcineurin-inhibitor-free "bottom-up" immunosuppressive regimen with basiliximab, mycophenolic acid, and steroids. The study objective is to evaluate the safety and clinical feasibility of MAPC admi

Who reads Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)?

Author

Felix C Popp; Barbara Fillenberg; Elke Eggenhofer; Philipp Renner; Johannes Dillmann; Volker Benseler; Andreas A Schnitzbauer; James Hutchinson; Robert Deans; Deborah Ladenheim; Cheryl A Graveen; Florian Zeman; Michael Koller; Martin J Hoogduijn; Edward K Geissler; Hans J Schlitt; Marc H Dahlke

Publisher

BioMed Central; Springer (Biomed Central Ltd.); London: BioMed Central, 2003-; Springer Science and Business Media LLC (ISSN 1479-5876)

Published

2011

Language

EN

Field

Biochemistry, Genetics and Molecular Biology (Life Sciences)